Cyteir Therapeutics, Inc. Common Stock
CYT
CYT was delisted on the 15th of March, 2024.
52 hedge funds and large institutions have $83.8M invested in Cyteir Therapeutics, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 21 increasing their positions, 9 reducing their positions, and 9 closing their positions.
133% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 9
44% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 9
8% more funds holding
Funds holding: 48 → 52 (+4)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
67% less capital invested
Capital invested by funds: $253M → $83.8M (-$170M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.57M |
| 2 |
EWM
Evercore Wealth Management
New York
|
+$835K |
| 3 |
BlackRock
New York
|
+$696K |
| 4 |
Millennium Management
New York
|
+$588K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$501K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$4.46M |
| 2 |
ABG
Ally Bridge Group
New York
|
-$3.63M |
| 3 |
CCM
CAAS Capital Management
New York
|
-$2.12M |
| 4 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$2.04M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.12M |
CYT Hedge Fund Activity: Q1 2022 in Review
52 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Cyteir Therapeutics, Inc. Common Stock (CYT) for Q1 2022, worth a combined $83.8M — down 67% from $253M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new CYT positions and 9 closed out — a net gain of 4 holders — while 21 added to existing stakes and 9 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $2.57M. The largest seller was Acuta Capital Partners, exiting entirely with an estimated $4.46M sold.
- 52 institutional investors held Cyteir Therapeutics, Inc. Common Stock (CYT) as of Q1 2022, up from 48 in Q4 2021.
- Funds reported $83.8M of Cyteir Therapeutics, Inc. Common Stock stock for Q1 2022, down 67% quarter-over-quarter.
- 13 funds opened new Cyteir Therapeutics, Inc. Common Stock positions in Q1 2022 and 9 closed out, a net change of +4 holders.
- The largest Cyteir Therapeutics, Inc. Common Stock buyer in Q1 2022 was Fidelity Investments, an estimated $2.57M added.
- The largest Cyteir Therapeutics, Inc. Common Stock seller in Q1 2022 was Acuta Capital Partners, an estimated $4.46M sold.
Based on aggregated 13F filings for Q1 2022.